Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses

• Published in: American journal of hematology Vol. 96; no. 4; pp. E95 - E98
• Main Authors: Brown, Jennifer R., Walker, Sarah R., Heppler, Lisa N., Tyekucheva, Svitlana, Nelson, Erik A., Klitgaard, Josephine, Nicolais, Maria, Kroll, Yasmin, Xiang, Michael, Yeh, Jennifer E., Chaudhury, Mousumi, Giaccone, Zachary T., Fernandes, Stacey M., Jacobsen, Eric D., Fisher, David C., Freedman, Arnold S., Davids, Matthew S., Supko, Jeffrey G., Wu, Catherine, Frank, David A.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01-04-2021; Wiley Subscription Services, Inc
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - therapeutic use; B-Lymphocytes - drug effects; B-Lymphocytes - metabolism; Cell Line, Tumor; Chronic lymphocytic leukemia; Dose-Response Relationship, Drug; Drug Repositioning; Drug Screening Assays, Antitumor; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic - drug effects; Hematology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Lymphatic leukemia; Male; Middle Aged; Neoplasm Proteins - antagonists & inhibitors; Neoplasm Proteins - biosynthesis; Neoplasm Proteins - genetics; Pharmacodynamics; Progression-Free Survival; Pyrimethamine; Pyrimethamine - administration & dosage; Pyrimethamine - pharmacology; Pyrimethamine - therapeutic use; Stat3 protein; STAT3 Transcription Factor - antagonists & inhibitors
• ISSN: 0361-8609; 1096-8652
• DOI: 10.1002/ajh.26084